Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?

To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. We herein report a case of complete remissi...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2014-12, Vol.34 (12), p.7361-7365
Main Authors: Gambini, Donatella, Locatelli, Elisa, Gianelli, Umberto, Bareggi, Claudia, Galassi, Barbara, Visintin, Roberto, Massironi, Sara, Dell'orto, Paolo G, Tomirotti, Maurizio
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - biosynthesis
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - surgery
Humans
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Kidney Neoplasms - surgery
Male
Middle Aged
Nephrectomy
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - secondary
Positron-Emission Tomography
Pyrroles - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.
ISSN:1791-7530